CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the expansion of the companys pipeline of small molecule candidates across a range of highly prevalent human diseases. These preclinical programs AMPK2 (AMP-activated protein kinase, 2 subunit), CTPS1 (CTP synthase 1), Cbl-b (Cbl proto-oncogene B), and WRN (Werner syndrome ATP-dependent helicase) represent promising targets across oncology, immunology and metabolism, for which Nimbus structure-based discovery approaches are uniquely suited.

The additional programs were unveiling today are a testament to Nimbus exceptional talent, the unwavering support of our investors, and the dynamic scientific collaborations we have built over the past decade, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. Our prolific pipeline reflects the breadth of potential we see for our discovery engine going forward, and a new chapter in Nimbus leadership of structure-based drug discovery. We look forward to progressing these programs forward to the clinic within our development organization, which advanced our ACC inhibitor to an early proof of mechanism and is currently progressing our Tyk2 inhibitor toward Phase II.

With the addition of these targets, weve built a pipeline of promising therapeutics for the treatment of patients with diseases that have limited or no therapeutic options, said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. Each of these targets represents the sweet spot for Nimbus approach they are known to be fundamental drivers of highly prevalent diseases but have proven difficult for the industry to drug. As we have demonstrated with our progress on HPK1, which is being presented at AACR this month, we believe our structure-based drug discovery engine can generate the potent, selective small molecule therapeutics needed to move the needle on these targets.

A brief overview of our newly disclosed programs follows:

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The companys LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. http://www.nimbustx.com

Go here to read the rest:
Nimbus Therapeutics Announces Expansion of Its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism - Business Wire